Mode
Text Size
Log in / Sign up
Phase 2 Completed N=389 Randomized Double-blind Treatment

BI 671800 ED in Steroid-naive Asthmatic Patients

Source: ClinicalTrials.gov NCT01092143 ↗
Enrolled (actual)
389
Serious AEs
0.5%
Results posted
May 2022
Primary outcomePrimary: Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment — -2.010; 1.073; 1.580; 1.967 FEV1 percent predicted — p=0.0311

Summary

This is a 6 week study to investigate the effectiveness and safety of BI 671800 ED in patients with asthma who do not take inhaled corticosteroids.

Outcome Measures

OutcomeResultp-value
PRIMARY
Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment
-2.010; 1.073; 1.580; 1.967; 6.610 0.0311 sig
SECONDARY
Asthma Control Questionnaire (ACQ) Mean Score Change From Baseline After Six Weeks of Treatment
-0.616; -0.543; -0.696; -0.677; -0.949 0.7413

Eligibility Criteria

Inclusion criteria

  • Signed informed consent consistent with ICH-GCP
  • Three month history of reversible (12% with 200 mL) asthma (according to GINA) with following spirometry at randomization: FEV1 60%-85%.
  • No ICS previous 3 months prior to screening.
  • Diagnosis of asthma prior to 40 years.
  • ACQ at least 1.5 at randomization.
  • Male or female, 18 to 65 years.
  • Non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine screen.
  • Able to perform PFT

Exclusion criteria

  • Significant diseases other than asthma or allergic rhinitis.
  • Hepatic transaminases or total bilirubin greater than 1.5 ULN.
  • Hospitalizations for asthma or asthma related intubation within 3 months.
  • Uncontrolled asthma.
  • Respiratory tract infection or exacerbation within 4 weeks.
  • FEV1 less than 40%, more than 12 puffs of SABA on more than two consecutive days or asthma exacerbation during the run-in period.
  • Participation in another interventional study.
  • Pregnant or nursing women.
  • Women of child bearing potential nor using appropriate methods of birth control as defined by protocol
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01092143). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search